Serious infections associated with anticytokine therapies in the rheumatic diseases.
about
Treatment of rheumatic diseases and hepatitis B virus coinfectionInduction of PNAd and N-acetylglucosamine 6-O-sulfotransferases 1 and 2 in mouse collagen-induced arthritis.Conidia but not yeast cells of the fungal pathogen Histoplasma capsulatum trigger a type I interferon innate immune response in murine macrophages.Granulomatous hepatitis secondary to histoplasma infection after treatment with infliximab.Disseminated Histoplasma capsulatum infection presenting with panniculitis and focal myositis in rheumatoid arthritis treated with etanercept.Long-term use of an antiinflammatory, curcumin, suppressed type 1 immunity and exacerbated visceral leishmaniasis in a chronic experimental model.Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritisImmunosuppression Adversely Affects TST but Not IGRAs in Patients with Psoriasis or Inflammatory Musculoskeletal Diseases.TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes.Host-mediated resolution of inflammation in periodontal diseases.Cells of the synovium in rheumatoid arthritis. Macrophages.Methods of evaluating immunotoxicity.Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease.Rheumatoid arthritis and the complement system.Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis.Tumor necrosis factor as a therapeutic target of rheumatologic disease.Infectious complications associated with monoclonal antibodies and related small moleculesCytokines and brain injury: invited review.Treatment of ankylosing spondylitis: focus on etanercept.Characterization of the Histoplasma capsulatum-induced granuloma.Presentation and outcome of histoplasmosis in pediatric inflammatory bowel disease patients treated with antitumor necrosis factor alpha therapy: a case series.The impact of biologic response modifiers on hepatitis B virus infection.Etanercept: efficacy and safety for approved indications.Management of coccidioidomycosis in patients receiving biologic response modifiers or disease-modifying antirheumatic drugs.Diagnosis and management of infectious complications of childhood rheumatic diseases.Reduction of chemokine secretion in response to mycobacteria in infliximab-treated patients.Biological therapy of psoriasis.Immune Modulation in the Treatment of Amyotrophic Lateral Sclerosis: A Review of Clinical Trials.Advances in the clinical management of GVHD.
P2860
Q28084305-433C8EB7-FF01-41D7-A18F-B70873133403Q33246701-7C866E17-584A-42A9-88A1-038FB53CF332Q34119470-03069068-F36A-4580-9E85-A52F4623A7FDQ34399044-D14AB48F-2902-43AE-8ED7-325FCC1D0BE0Q34607722-E0146B46-2C7D-4084-AFCA-DB33690D1F58Q34665258-6CCD8735-77FB-445C-9088-7A1CC7AB0C17Q35759985-05271C7A-F9C3-4BAA-AF0F-D109C2680145Q35993903-702E822E-AD3A-4B71-B75B-C20D9CA01774Q36236659-B404CCA6-7F50-4051-BA81-0D0CC35D5766Q36362712-25DE98C9-D0BA-4D89-B38C-FD863AB7BA6EQ36465497-04C297B2-D58A-4DE4-A155-69CA4EC753DAQ36546265-5BADC479-44EB-4EF7-8FAC-F498F309FD11Q36615576-3851D72D-7B89-4A3C-A653-E6D4A8A19621Q36939396-3FF74369-FBD9-49A5-86CD-B11D2AC0994BQ36955347-055E4838-33A6-4AC8-A399-7FD3513AAAA0Q37008829-08D88FFD-EFE5-42A4-A977-E503007A4265Q37156636-44FB0604-B68E-467D-9EBA-312992F001C4Q37173555-B06551AD-F0D6-490C-9541-18ECF4FFAFC5Q37290601-7DBC0887-2836-49D7-9014-4E4A79CBD769Q37357512-56E7B2A4-B6EC-4E99-BF5F-C41A30E2C349Q37774323-D541C6F4-D1C3-45A0-91E7-6F67648771A9Q37832503-007C3FC1-91F9-4ED3-864C-5CA870543F83Q37954714-4FAED760-2E13-4D0F-9755-19C3AA47EDDCQ38022576-53A47366-B7BF-448E-81E4-74413B2B77D2Q38084889-79F3CBB5-056A-42D5-896C-DB15A117A8D8Q39301083-D049E8ED-F297-413B-915A-5CC02938C48DQ41145989-4B6CB332-ABA2-498B-8082-E499BEDBDB83Q42367893-63D41AB3-7324-4F1B-9A57-8B47014DC789Q43170920-E92ECB1E-1965-4DE2-8059-536141317D28
P2860
Serious infections associated with anticytokine therapies in the rheumatic diseases.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Serious infections associated with anticytokine therapies in the rheumatic diseases.
@ast
Serious infections associated with anticytokine therapies in the rheumatic diseases.
@en
type
label
Serious infections associated with anticytokine therapies in the rheumatic diseases.
@ast
Serious infections associated with anticytokine therapies in the rheumatic diseases.
@en
prefLabel
Serious infections associated with anticytokine therapies in the rheumatic diseases.
@ast
Serious infections associated with anticytokine therapies in the rheumatic diseases.
@en
P2860
P356
P1476
Serious infections associated with anticytokine therapies in the rheumatic diseases.
@en
P2093
Joan M Bathon
Jon T Giles
P2860
P304
P356
10.1177/0885066604267854
P577
2004-11-01T00:00:00Z